1197375-13-5 Usage
Description
(4S,6R)-5,6-Dihydro-4-hydroxy-6-Methylthieno[2,3-b]thiopyran-7,7-dioxide, commonly known as sulbactam, is a beta-lactamase inhibitor with potent antimicrobial properties. It is characterized by its ability to inhibit the activity of beta-lactamases, enzymes produced by bacteria that can deactivate certain antibiotics. This unique feature allows the antibiotic to remain active and effectively eliminate the bacteria causing the infection.
Uses
Used in Pharmaceutical Industry:
Sulbactam is used as a beta-lactamase inhibitor for the treatment of bacterial infections. It is particularly effective when used in combination with antibiotics such as ampicillin or cefoperazone, enhancing their efficacy against a wide range of bacterial infections, including those caused by multi-drug resistant bacteria.
Used in Combination Therapy:
Sulbactam is used in combination therapy with certain antibiotics to increase their effectiveness against bacterial infections. By inhibiting the activity of beta-lactamases, sulbactam allows the antibiotic to remain active and effectively kill the bacteria, making it a valuable component in the fight against antibiotic resistance.
Used in Treating Multi-Drug Resistant Bacterial Infections:
Sulbactam is employed in the treatment of infections caused by multi-drug resistant bacteria. Its ability to inhibit beta-lactamases makes it a crucial component in combination therapies, helping to overcome the challenges posed by antibiotic resistance and improving patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 1197375-13-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,7,3,7 and 5 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1197375-13:
(9*1)+(8*1)+(7*9)+(6*7)+(5*3)+(4*7)+(3*5)+(2*1)+(1*3)=185
185 % 10 = 5
So 1197375-13-5 is a valid CAS Registry Number.
1197375-13-5Relevant articles and documents
ASYMMETRIC REDUCTION PROCESS
-
Page/Page column 13; 14, (2012/09/22)
The present invention relates to a stereoselective reduction procedure to obtain, by means of catalytic asymmetric hydrogenation by hydrogen transfer, a compound of formula (I) in which X is S or SO2 and R4 is hydrogen or an SO2NH2 group, from the corresponding ketone precursor, said compound of formula (I) being useful as an intermediate in the preparation of dorzolamide or of the hydrochloride salt thereof.
